Skip to content

A study to determine the curative effect and mechanism of Apatinib combined with chemotherapy for SD patients with advanced malignant solid tumor

A study to determine the curative effect and mechanism of Apatinib combined with chemotherapy for SD patients with advanced malignant solid tumor

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-16009849
Enrollment
Unknown
Registered
2016-11-14
Start date
2016-10-23
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Sponsors

the First affiliated Hospital of SooChow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years old to 75 years old, male or female; 2. According to RECIST version 1.1 standard (appendix), the patient has at least one extracranial measurable lesions (Spiral CT scans =10 mm, CT scanning layer is not more than 5 mm thick), it can be measured that lesions has not received radiotherapy; 3. To chemotherapy curative effect evaluation of SD patients with advanced malignant solid tumor; 4. ECOG physical status score: 0~2 points; 5. Expected lifetime acuity =3 months; 6. major organs functioning properly; 7. Women of childbearing age must be enrolled in the 7 days before a pregnancy test (serum or urine) results were negative, and the voluntary during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception; for men, surgical sterilization should be, or agreed during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception; 8. signed informed consent, compliance is good and agreed to cooperate with the survival of follow-up.

Exclusion criteria

Exclusion criteria: 1. suffering from hypertension, the antihypertensive drug therapy can not be reduced to the normal range (systolic blood pressure> 140 mmHg / diastolic blood pressure> 90 mmHg); 2. suffered from severe cardiovascular disease: with =level II of coronary heart disease, arrhythmia (including QTc interval prolongation men> 450 ms, female> 470 ms) and heart failure; 3. urine routine urinary protein is more than + + and confirmed the 24 hour urinary protein quantitative >1.0 g; 4. researchers consider patients with digestive tract bleeding tendacy; 5. Coagulation dysfunction, with bleeding tendency; 6. with psychotropic drug abuse history and can't get rid of or have mental disorders; 7. according to the investigator's judgment, there is a serious harm to patients' safety or the influence of patients' complete study of accompanying diseases; 8. The transfer of the central nervous system with symptoms; 9. A pregnant or lactating women; 10. researchers considered unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
disease control rate;

Countries

China

Contacts

Public ContactZhu Chunrong

the First affiliated Hospital of SooChow University

zcr050311@163.com+86 13063870566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026